WO1990014358A1 - T-lymphotropic retrovirus monoclonal antibodies - Google Patents
T-lymphotropic retrovirus monoclonal antibodies Download PDFInfo
- Publication number
- WO1990014358A1 WO1990014358A1 PCT/US1990/002874 US9002874W WO9014358A1 WO 1990014358 A1 WO1990014358 A1 WO 1990014358A1 US 9002874 W US9002874 W US 9002874W WO 9014358 A1 WO9014358 A1 WO 9014358A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hiv
- amino acid
- antibodies
- antigen
- antibody
- Prior art date
Links
- 241001430294 unidentified retrovirus Species 0.000 title description 6
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 52
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims abstract description 51
- 238000001514 detection method Methods 0.000 claims abstract description 21
- 239000000427 antigen Substances 0.000 claims description 33
- 102000036639 antigens Human genes 0.000 claims description 33
- 108091007433 antigens Proteins 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 238000009007 Diagnostic Kit Methods 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 230000008827 biological function Effects 0.000 claims 4
- 238000002965 ELISA Methods 0.000 abstract description 23
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 21
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 19
- 238000003556 assay Methods 0.000 abstract description 18
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 17
- 108090000623 proteins and genes Proteins 0.000 abstract description 15
- 102100023321 Ceruloplasmin Human genes 0.000 abstract description 4
- 108090000565 Capsid Proteins Proteins 0.000 abstract description 3
- 101710205625 Capsid protein p24 Proteins 0.000 description 22
- 101710177166 Phosphoprotein Proteins 0.000 description 22
- 101710149279 Small delta antigen Proteins 0.000 description 22
- 102100031987 Transmembrane emp24 domain-containing protein 2 Human genes 0.000 description 22
- 101710072850 Poxin Proteins 0.000 description 14
- 101710142282 Protein P26 Proteins 0.000 description 14
- 102100032106 Transmembrane emp24 domain-containing protein 3 Human genes 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 12
- 230000036436 anti-hiv Effects 0.000 description 8
- 239000006166 lysate Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 101710177291 Gag polyprotein Proteins 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000002976 reverse transcriptase assay Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 101100440992 Drosophila melanogaster Crag gene Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108010015780 Viral Core Proteins Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101710121996 Hexon protein p72 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019910700048A KR0168447B1 (en) | 1989-05-15 | 1990-05-14 | T-lymphotropic retrovirus monoclonal antibodies |
FI915333A FI915333A0 (en) | 1989-05-15 | 1991-11-12 | MONOCLONAL ANTIKROPPAR MED T-LYMPOTROPA RETROVIRUS. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35188289A | 1989-05-15 | 1989-05-15 | |
US351,882 | 1989-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990014358A1 true WO1990014358A1 (en) | 1990-11-29 |
Family
ID=23382831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/002874 WO1990014358A1 (en) | 1989-05-15 | 1990-05-14 | T-lymphotropic retrovirus monoclonal antibodies |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0472659A4 (en) |
JP (1) | JPH04505621A (en) |
KR (1) | KR0168447B1 (en) |
AU (1) | AU642886B2 (en) |
CA (1) | CA2032509A1 (en) |
FI (1) | FI915333A0 (en) |
WO (1) | WO1990014358A1 (en) |
ZA (1) | ZA903492B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992016551A1 (en) * | 1991-03-25 | 1992-10-01 | Carlbiotech Ltd. A/S | Small peptidic compounds useful for the treatment of glaucoma |
WO1992022572A1 (en) * | 1991-06-13 | 1992-12-23 | Replico Medical Ab | New hiv-1 gag and env peptides, diagnostic |
FR2777285A1 (en) * | 1998-04-10 | 1999-10-15 | Bio Merieux | PEPTIDE LIGAND HAVING SPECIFIC AFFINITY TO PROTEIN P24 OF RETROVIRUS HIV-1 |
WO2002064615A2 (en) * | 2000-12-06 | 2002-08-22 | Abbott Laboratories | Monoclonal antibodies to human immunodeficiency virus and uses thereof |
EP1849869A3 (en) * | 1994-10-20 | 2011-05-18 | Institut Pasteur | Nucleotide sequences of HIV-1 group (or sub-group) 0 retroviral antigens |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4755457A (en) * | 1985-02-05 | 1988-07-05 | Robert Guroff Marjorie | Method for detecting HTLV-III neutralizing antibodies in sera |
US4843011A (en) * | 1985-08-01 | 1989-06-27 | Akzo N.V. | Monoclonal antibodies for binding HTLV-III proteins, and cell lines for their production |
US4888290A (en) * | 1987-11-06 | 1989-12-19 | Coulter Corporation | Monoclonal antibody specific to HIV antigens |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0330359A3 (en) * | 1988-02-25 | 1991-06-05 | Bio-Rad Laboratories, Inc. | Composition useful in the diagnosis and treating of hiv-1 infection |
US5173399A (en) * | 1988-06-10 | 1992-12-22 | Abbott Laboratories | Mouse monoclonal antibodies to hiv-1p24 and their use in diagnostic tests |
CA2017021A1 (en) * | 1989-05-22 | 1990-11-22 | Johannes Jacobus Schalken | Diagnostic test for detecting antibodies directed against antigens of one or more related viruses |
DE4039925A1 (en) * | 1990-12-14 | 1992-06-17 | Behringwerke Ag | SELECTED PEPTIDES OF THE GROUP-SPECIFIC ANTIGEN (GAG) OF HUMANEM IMMUNE DEFICIENCY VIRUS (HIV), THEIR PRODUCTION AND USE |
-
1990
- 1990-05-08 ZA ZA903492A patent/ZA903492B/en unknown
- 1990-05-14 WO PCT/US1990/002874 patent/WO1990014358A1/en not_active Application Discontinuation
- 1990-05-14 EP EP19900909217 patent/EP0472659A4/en not_active Ceased
- 1990-05-14 AU AU58355/90A patent/AU642886B2/en not_active Ceased
- 1990-05-14 CA CA002032509A patent/CA2032509A1/en not_active Abandoned
- 1990-05-14 JP JP2508986A patent/JPH04505621A/en active Pending
- 1990-05-14 KR KR1019910700048A patent/KR0168447B1/en not_active IP Right Cessation
-
1991
- 1991-11-12 FI FI915333A patent/FI915333A0/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4755457A (en) * | 1985-02-05 | 1988-07-05 | Robert Guroff Marjorie | Method for detecting HTLV-III neutralizing antibodies in sera |
US4843011A (en) * | 1985-08-01 | 1989-06-27 | Akzo N.V. | Monoclonal antibodies for binding HTLV-III proteins, and cell lines for their production |
US4888290A (en) * | 1987-11-06 | 1989-12-19 | Coulter Corporation | Monoclonal antibody specific to HIV antigens |
Non-Patent Citations (5)
Title |
---|
Biological Abstracts, Vol. 80, No. 10, issued 15 November 1985, V. DI MARZO et al., "Monoclonal antibodies specific for p24, the major core protein of human T cell leukemia virus type III". See page 587, col. 2, the Abstract No. 87756. * |
Biological Abstracts, Vol. 84, No. 1, issued 01 July 1987, T. HATTORI et al., "Characteracterization of three monoclonal antibodies (VAK3-5) that identify p24, core protein of human immunodeficiency virus and its precursors". See page 499, col. 1, the Abstract No. 445.9. * |
Biological Abstracts, Vol. 86, No. 10, issued 15 November 1988, M. NIEDRIG et al., "Monoclonal antibodies directed against human immunodeficiency virus (HIV) gag proteins with specificity for conserved epitopes in HIV-2 and simian immunodeficiency virus". See page 1270, col. 1, the Abstract No. 109338. * |
Biological Abstracts, Vol. 87, No. 10, issued 15 May 1989, P, KUSK et al., "Immunological characterization and detection of the major core protein p24 of the human immunodefiency virus (HIV) using monoclonal antibodies". See page 1146, col. 1, the Abstract No. 110752. * |
See also references of EP0472659A4 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992016551A1 (en) * | 1991-03-25 | 1992-10-01 | Carlbiotech Ltd. A/S | Small peptidic compounds useful for the treatment of glaucoma |
WO1992022572A1 (en) * | 1991-06-13 | 1992-12-23 | Replico Medical Ab | New hiv-1 gag and env peptides, diagnostic |
EP1849869A3 (en) * | 1994-10-20 | 2011-05-18 | Institut Pasteur | Nucleotide sequences of HIV-1 group (or sub-group) 0 retroviral antigens |
FR2777285A1 (en) * | 1998-04-10 | 1999-10-15 | Bio Merieux | PEPTIDE LIGAND HAVING SPECIFIC AFFINITY TO PROTEIN P24 OF RETROVIRUS HIV-1 |
WO1999053063A1 (en) * | 1998-04-10 | 1999-10-21 | Bio Merieux | PEPTIDE LIGAND HAVING SPECIFIC AFFINITY FOR THE HIV1 RETROVIRUS p24 PROTEIN |
US7531638B2 (en) | 2000-12-06 | 2009-05-12 | Abbott Laboratories, Inc. | Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26) |
US6818392B2 (en) | 2000-12-06 | 2004-11-16 | Abbott Laboratories | Monoclonal antibodies to human immunodeficiency virus and uses thereof |
US7528238B2 (en) | 2000-12-06 | 2009-05-05 | Abbott Laboratories, Inc. | Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26) |
WO2002064615A3 (en) * | 2000-12-06 | 2003-04-17 | Abbott Lab | Monoclonal antibodies to human immunodeficiency virus and uses thereof |
US7531642B2 (en) | 2000-12-06 | 2009-05-12 | Abbott Laboratories, Inc. | Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26). |
US7531641B2 (en) | 2000-12-06 | 2009-05-12 | Abbott Laboratories, Inc. | Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26) |
US7531640B2 (en) | 2000-12-06 | 2009-05-12 | Abbott Laboratories, Inc. | Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26) |
US7531639B2 (en) | 2000-12-06 | 2009-05-12 | Abbott Laboratories, Inc. | Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26) |
US7897332B2 (en) | 2000-12-06 | 2011-03-01 | Abbott Laboratories | Methods for the detection of HIV-1 or -2 antigens employing monoclonal antibodies that recognize a shared HIV-1/-2 epitope in the capsid p24/p26 proteins |
WO2002064615A2 (en) * | 2000-12-06 | 2002-08-22 | Abbott Laboratories | Monoclonal antibodies to human immunodeficiency virus and uses thereof |
EP2336175A1 (en) * | 2000-12-06 | 2011-06-22 | Abbott Laboratories | Monoclonal antibodies to human immunodeficiency virus and uses thereof |
US9115189B2 (en) | 2000-12-06 | 2015-08-25 | Abbott Laboratories | Monoclonal antibodies to human immunodeficiency virus and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP0472659A4 (en) | 1992-04-08 |
ZA903492B (en) | 1991-02-27 |
KR920701243A (en) | 1992-08-11 |
FI915333A0 (en) | 1991-11-12 |
EP0472659A1 (en) | 1992-03-04 |
AU642886B2 (en) | 1993-11-04 |
AU5835590A (en) | 1990-12-18 |
KR0168447B1 (en) | 1999-01-15 |
CA2032509A1 (en) | 1990-11-16 |
JPH04505621A (en) | 1992-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6013484A (en) | HIV-3 retrovirus and its use | |
EP0201540B2 (en) | Envelope antigens of lymphadenopathy associated virus and their applications | |
Palker et al. | Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46. | |
AU2009213045B2 (en) | Nucleotide sequences of HIV-1 type (or subtype) O retrovirus antigens | |
US4888290A (en) | Monoclonal antibody specific to HIV antigens | |
JP2958346B2 (en) | Anti-HIV-2 monoclonal antibody and method for detecting anti-HIV-2 gp41 antibody using the same | |
US5210181A (en) | T-lymphotropic retrovirus peptide | |
US5254457A (en) | Monoclonal antibodies and method for identifying different aids-related viruses | |
Avrameas et al. | Localisation of three epitopes of the env protein of feline immunodeficiency virus | |
AU642886B2 (en) | T-lymphotropic retrovirus monoclonal antibodies | |
Boucher et al. | Immune response and epitope mapping of a candidate HIV‐1 p17 vaccine HGP30 | |
Walther et al. | Evaluation of HIV-1/HIV-2 immunoblots for detection of HIV-2 antibodies | |
Rimmelzwaan et al. | Gag-and env-specific serum antibodies in cats after natural and experimental infection with feline immunodeficiency virus | |
Lombardi et al. | Detection of B epitopes on the p24 gag protein of feline immunodeficiency virus by monoclonal antibodies | |
van Tijn et al. | Antigenicity of Linear B-Cell Epitopes in the C1, V1, and V3 Region of HIV-1 gp120 | |
US5624795A (en) | Isolation and characterization of a novel chimpanzee lentivirus, designated simian immunodeficiency virus isolate cpz-ant | |
Kienzle et al. | Immunological study of the Nef protein from HIV-1 by polyclonal and monoclonal antibodies | |
Cogniaux et al. | Characterization of monoclonal antibodies against the p17 core protein of the human immunodeficiency virus 1 | |
Gallina et al. | Major antigenic domain recognized by monoclonal antibodies maps within the carboxy‐terminal moiety of a recombinant human immunodeficiency virus‐1 p24 protein | |
Bodéus et al. | An anti-HIV-1 gag protein rat monoclonal antibody library | |
EP1568767A2 (en) | Dna fragments of lav genes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI JP KR |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2032509 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990909217 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 915333 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1990909217 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1990909217 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990909217 Country of ref document: EP |